(Reuters) -Drugmaker Eli Lilly is in advanced talks to acquire gene-editing startup Verve Therapeutics for up to $1.3 billion ...

Verve Therapeutics stock jumped after a report said pharmaceutical giant Eli Lilly is in advanced talks to buy the ...

In April, Verve tweaked the development of the first PCSK9 inhibitor in its programme (VERVE-101) after a trial revealed ...

Eli Lilly is in talks to buy gene editing partner Verve Therapeutics for up to $1.3 billion, according to a report in ...

Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks to acquire gene editing biotech Verve Therapeutics Inc.

As part of the deal, Eli Lilly would pay almost $1bn upfront for Verve, which is developing a gene-editing therapy to treat bad cholesterol, and a further $300mn based on the biotech company achieving ...

At 5:33 a.m. ET, Dow E-minis were down 269 points, or 0.63%, S&P 500 E-minis were down 37.25 points, or 0.62%. Nasdaq 100 ...

SunRun shares are plunging 25%, SolarEdge Technologies stock is diving 20%, and Enphase Energy is sliding 15% after Senate Republicans proposed [an end to win ...

Oil demand will peak at 105.6 million barrels per day (bpd) by 2029 and then fall slightly in 2030, a table in the Paris-based IEA’s annual report shows. At the same time, global production capacity ...

In the closing of the recent trading day, Eli Lilly (LLY) stood at $807.58, denoting a -1.44% move from the preceding trading day.

The Bahamas is preparing to cancel contracts with Cuban healthcare professionals after discussions with the U.S. government, Bahamian Health Minister Michael Darville said in a parliamentary address ...

Amazon.com's annual Prime Day sales event is scheduled for July 8 through July 11, expanding to four days from two days ...